To enhance global control of encephalitis and hepatitis caused by rabies-(RABV), Japanese encephalitis-(JEV), hepatitis B-virus (HBV), and enterovirus 71 (EV71) novel immunisation strategies are needed. Therefore, a multipathogen modified Vaccinia Ankara vector, expressing antigens from the above pathogens, was constructed. Two recombinants, one carrying the EV71 and JEV pathogen sequence and one the RABV-HBV pathogen sequence were generated. To ensure similar expression of the antigens, a T7-promoter was linked to the expression cassettes of all pathogen sequences. Direct regulation of this promoter was achieved through co-infection with a second T7-polymerase 2 expressing MVA. Protein expression using this co-infection model of expression was demonstrated in vitro. To investigate the co-infection model of antigen delivery in vivo, a murine immunogenicity study was performed using the MVA-RABV-HBV recombinant. Although, serum antibodies against MVA were induced in all mice, no serum antibodies against RABV or HBV could be detected.
Introduction
The last decade has seen a plethora of new vaccine approaches not only for the traditional prevention of infectious diseases, but also therapeutic vaccines. Success in clinical trials and subsequent licensing of these products will pose the question as to which products to include in routine vaccine schedules and therapeutic plans. One means to avoid overloading vaccination schedules is the combination of several vaccines into one product. This would require reformulating previously licensed and established vaccines which may be problematic as many monovalent vaccines require a distinct formulation (e.g. adjuvants) to confer protection. Alternative methods of antigen delivery that do not require additional substances, such as adjuvants, to generate a protective immune response include viral vectors. Many novel vaccine approaches have used viruses as delivery vehicles for one or more foreign antigens. Of special interest are larger viruses such as poxviruses or adenoviruses, where there are fewer restrictions imposed by packaging limits, which may be deployed to express various antigens at once (multivalent or multipathogen viral vector vaccines).
In this present paper we investigated the potential application of Modified Vaccinia Ankara (MVA, a well-established vaccine vector) as a multipathogen vaccine candidate. Foreign antigens were inserted into different locations in the MVA genome. Each antigen was linked to a T7-promoter and only expressed after co-infection with a second MVA, expressing the T7-polymerase from a poxviral promoter.
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Methods
Cells
Primary chicken embryo fibroblasts (pCEF) were prepared as described previously [1] . Human lung embryo fibroblasts (MRC5) were purchased from Sigma-Aldrich (Cat.No.#05090501). The cells were cultivated antibiotic free in Dulbecco's modified essential eagle medium (Sigma-Aldrich;
Cat.No.#301305) supplemented with 10% fetal calf serum (FCS, Biosera, Gentaur Ltd.; Cat.No.#FB-13770/500) and 2 mM L-Glutamine (Sigma-Aldrich; Cat.No.#G7513).
Virus
Wildtype MVA (wtMVA) was kindly provided by Anton Mayr (Ludwigs Maximilian University, Munich, Germany). The virus titre was estimated by plaque assay in pCEFs. Tenfold dilutions of the virus-stock sample in DMEM medium were adsorbed on pCEFs. The cells were then overlaid with 2% low melting point agarose (Sigma-Aldrich; Cat.No.#A9045) with 2X MEM (Life Technologies Ltd.; Cat.No.#11935-046) medium and 10% FCS in a 50:50 ratio. The plates were then incubated at 37°C with 5% CO 2 and 95% humidity until plaques were visible.
Generation of plasmids
Expression cassettes for insertion into the MVA genome were designed using the Lasergene software package (DNASTAR Inc., Madison, USA MVA deletion site 1 (pMVA1-RABV-HBV), the JEV sequence was cloned into the transfer plasmid for insertion into deletion site 6 (pMVA6-JEV), and the EV71 sequence and the T7 polymerase were cloned into the transfer plasmid for insertion into deletion site 2 respectively (pMVA2-EV71, pMVA2-T7). All transfer plasmids were sequenced prior to their use in generating recombinant MVA.
Generation of recombinant MVA
pCEFs were transfected with pMVA2-EV71, pMVA6-JEV, pMVA2-T7pol, or pMVA1-RABV-HBV using SuperFect Transfection Reagent (QIAGEN; Cat.No.#301305) following the manufacturers' guidelines.
Transfected cells were then infected with MVA at a multiplicity of infection of 0.05 (PFU/cell). The resulting recombinant MVA was serially plaque-purified 10 times in pCEFs, using beta-galactosidase plaque assay [2] . Recombinant MVA was amplified on pCEF cells, purified by sucrose cushion centrifugation [3] and titrated by plaque assay [4] 
Generation of recombinant baculoviruses
To create recombinant baculoviruses, the BacMagic DNA Kit (Merck Millipore, Hertfordshire, UK;
Cat.No.#72350-3) was used according to the manufacturers' instructions. The transfer plasmids containing the four pathogen sequences were generated using the 3C-Lic cloning Kit (Novagen; performed to obtain whole blood.
Results and Discussion
Construction of transfer plasmids
The transfer plasmids used for homologous recombination encoded antigenic sequences with a T7
promoter or the T7polymerase with a poxviral p7.5 promoter, flanked by MVA genomic sequences for insertion into deletion site 1, 2 or 6 of MVA [5] . Each transfer plasmid encoded the LacZ gene downstream of the p11 poxvirus promoter for transient color selection [2, 6, 7] . Figure 1 gives a schematic overview of the transfer plasmids. 
Generation of recombinant MVA
The generation of the recombinant MVAs (rMVA) required two independent recombination events.
In the first recombination event the whole plasmid DNA was inserted in the viral genome into the respective deletion site. The uptake of the whole plasmid was monitored using beta-galactosidase assay by screening for blue virus plaques. In the second intragenomic recombination event, the marker and the rest-sequence were eliminated. In regard to a complex vaccine for human use, the construction of a marker-free variant is very desirable. To confirm the retention of the expression cassettes and loss of the LacZ marker/rest-plasmid in the different deletion sites of MVA, virus 10 plaques were screened with specific primer sets (see Table 1 ). Figure 2 shows a schematic representation of the different multipathogen recombinants, one expressing antigens from a single locus in the MVA genome with a bidirectional promoter, the other expressing two individual antigens from two different loci in the genome. 
In vitro expression of recombinant proteins from a baculovirus expression system
To confirm the expression of recombinant proteins from AcNPV, Western blots were performed. Each protein was expressed with a histidine-tag, therefore, an anti-his antibody could be used to detect all four proteins (figure 3). The predicted size was calculated from the deduced amino acid sequence.
The Western blots show additional reactive proteins. These could represent degradation or aggregation of the expressed protein. It is also known that the anti-his antibody partially binds an unknown, probably histidine-rich insect cell protein with a size of approximately 100 kDa. Results of Western blot and dot blot analysis of mouse sera showed no detectable antibody against rabies glycoprotein or hepatitis B surface antigen. The candidate vaccine, however, was delivered correctly, as all of the injected mice produced antibodies against the viral vector.
In this multipathogen appoach the T7-promoter/T7-RNA polymerase was used to drive expression of transgenes in MVA. As efficient expression of antigens is important in vaccines, the T7-expression system seemed ideal because of its strict promoter specificity and high catalytic activity and several studies have shown the successful application of the T7-system in poxviruses in vitro. Three different approaches have been taken: Cells transfected with plasmid-T7pol and infected with rMVA, cells infected with rMVA and MVA-T7pol, or, cells transfected with plasmid DNA carrying the transgenes and infected with MVA-T7pol [8] [9] [10] [11] . None of these studies have advanced to animal or clinical studies. In this project we showed with immunocytochemistry, Western blot and dot-blot analysis that recombinant proteins can be expressed from MVA in vitro when using the T7-expression system and the co-infection model of gene expression. To our knowledge, this study was the first to investigate the co-infection method employing the T7-expression system in vivo. This system might not be applicable to in vivo situations as it might not be possible for two MVAs to infect the same host cell, which is a prerequisite for antigen expression. Alternatives to our conditional-gene expression approach would be poxviral promoters, such as p7.5, mH5, PrS (all early-late promoters), I1L (intermediate-late promoter), or M13.5L (very early promoter) [12] [13] [14] [15] [16] [17] . Although, gene expression would have been guaranteed using the poxviral promoter (several successful in vivo studies have used poxviral promoters), we would have less control over the expression of transgenes.
As already mentioned above, a vaccine candidate expressing different influenza virus genes employing different poxviral promoters (PsynI, PsynII and H5 promoters) was able to generate antibodies in mice that protected mice from a lethal challenge with several influenza viruses [18] .
Therefore, an approach following this model of gene expression might have improved our proposed vaccine candidate. As mentioned above a reason for the failure to produce detectable antibodies may be the inability of two MVA to infect the same cell. Viral interference or superinfection resistance (SIE) is defined as the reduced susceptibility of a cell to re-infection, after an established primary infection [19] . The inhibition of a secondary infection is mainly due to occupation or downmodulation of cellular receptors. This phenomenon has been reported for vaccinia virus (VACV) -like MVA, a member of the orthopoxvirus family -and might explain why no antibodies for HBsAg or RABV-G were observed in the conducted mouse study [20] [21] [22] . The virus might facilitate the inhibition of a re-infection through various mechanisms. Laliberte and colleagues [20] reported both the entry of the core into the cell and early gene expression, but not viral DNA replication, as a prerequisite for VACV to induce SIE in vivo (mouse model). Earlier studies have also found that VACV late proteins A56 and K2 are involved in blocking the entry of a secondary virus. Moreover, it was shown, that VACV was able to block the entry of related poxviruses but not heterologous viruses such as West Nile virus or vesicular stomatitis virus [23] [24] [25] [26] . The various steps leading up to SIE and the exact timeline are not understood in their entirety and might vary for MVA. In this project, both poxviruses (MVA-RABV-HBV & MVA-T7pol) were administered simultaneously, as we believed that this would reduce the chances for one virus to establish mechanisms responsible for SIE. This assumption is highly speculative as there are no in vivo data available on the topic of SIE with MVA.
However, if proven true, the issue of SIE could be easily circumvented by using a heterologous virus (e.g. Adenovirus) or a plasmid to express the T7-polymerase.
Another explanation for the lack of antibodies in the vaccinated mice could be MVA immunodominance. Immunodominance is characterised by the ability of one or a few strong antigens to stimulate a strong cellular or humoral immune response (dominant epitopes). Sub-dominant epitopes are therefore targeted to a lower degree or not at all [27] . In the co-infection model of antigen expression, the first expressed viral genes are MVA-own genes. Although, there are no data of when exactly the inserted pathogen sequences are expressed when using the co-infection model, it is possible that the immune response will be directed against dominant poxviral epitopes while silencing the immune response towards LHBsAg and RABV-G. Previous experiments have shown that there is a correlation between antigens expressed early in the infection cycle and immunodominance [28, 29] . If true, this would render the co-infection model of antigen expression inoperative in its current state. Possible solutions would be the administration of a plasmid expressing the T7-polymerase prior to the administration of MVA-RABV-HBV, or the use of a different promoter system at all to express the transgenes in the very early stages of the infection. The former would be rather difficult to transfer to clinical applications.
Many traditional vaccine approaches have used the repeated administration of the same vaccine to generate protective immunity in humans (homologous primer-boost). For this reason we designed our murine immunogenicity study following the homologous prime-boost model. In recent years it has been found that heterologous prime-boost regimens exceed immune responses received with homologous prime-boost regimens [30, 31] . In fact, several studies have found that MVA is most potent when used as a booster following a prime immunisation with a heterologous virus (e.g.
Adenovirus) or DNA [32] [33] [34] [35] [36] [37] [38] [39] . Moreover, it has been shown that subsequent booster vaccinations with MVA following a prime immunisation with the same MVA can only marginally increase the immunogenicity of a vaccine [32] . Considering this, perhaps a DNA-vaccine expressing RABV-G and LHBsAg might be a better option for priming. The DNA vaccine could be generated using a commercially available vaccine plasmid such as pVAX1 (Cat.No.#V26020, Thermo Fisher Scientific), which has been widely used for generating DNA-vaccines [40, 41] . Instead of using a homologous prime-boost approach including MVA only, a heterologous prime-boost regimen with an initial DNAvaccination followed by a MVA-booster might lead to a successful immunisation and the generation of antibodies.
The immune response towards a vaccine candidate is not only dependent on the vaccine formulation itself, the right immunisation schedule paired with the route of administration can decide between success and failure. In this study, we proposed a one-fits-all approach -we assumed that one route of administration and one specific vaccination schedule could lead to protection against several diseases. The murine immunogenicity study investigating the MVA-RABV-HBV/MVA-T7pol vaccine candidate was conducted with vaccine administration only two weeks apart. The mice were sacrificed two weeks after the booster vaccination. Potentially, this vaccination schedule was too short to generate a measurable immune response against the LHBsAg and RABV-G using the co-infection model. Other murine immunogenicity studies investigating multipathogen MVA vaccines used a twostep protocol (day 0, day 28) of 100µL of 8x10 7 TCID 50 with a MVA vaccine candidate expressing different influenza virus genes (H5N1 clade). This vaccine candidate was able to generate antibody levels that protected mice from a lethal challenge with H5N1 viruses [18] .
Conclusion
In summary, we were able to demonstrate that two transgenes, when inserted into one or two different loci in the MVA genome, can be expressed in vitro when using the co-infection model of gene expression with a T7-expression system. This project has provided new insights into a novel group of vaccines, the multipathogen viral vector vaccines, employing MVA as a vector. Future studies will be needed to further explore this vaccine-group, as well as the co-infection model of expression.
